Evidence map›Paper›PMID 19886840›Full record

ArticleAIDS research and human retroviruses2009

Estrogen receptor alpha inhibits the estrogen-mediated suppression of HIV transcription in astrocytes: implications for estrogen neuroprotection in HIV dementia.

Paula M Heron, Jadwiga Turchan-Cholewo, Annadora J Bruce-Keller, Melinda E Wilson

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Estrogen and viral infection.Frontiers in immunology · 2025
    Review
  6. Article
  7. Review
  8. Endolysosome Localization of ERα Is Involved in the Protective Effect of 17α-Estradiol against HIV-1 gp120-Induced Neuronal Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  9. Article
  10. Article
  11. Possible protective role of 17β-estradiol against COVID-19.Journal of allergy and infectious diseases · 2020
    Article
  12. Article
  13. Article
  14. Barriers to a cure for HIV in women.Journal of the International AIDS Society · 2016
    Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Paula M HeronDepartment of Physiology, University of Kentucky Medical Center, Lexington, Kentucky 40536-0298, USA.
Jadwiga Turchan-Cholewo
Annadora J Bruce-Keller
Melinda E Wilson
University of Kentucky · US

Funding

PROTECTIVE ACTIONS OF ESTRADIOL/SERMS ON BRAIN/HIVP20RR015592 · NCRR · UNIVERSITY OF KENTUCKY · PI KELLY, THOMAS J. · 2000 to 2009
$18.2M
National NeuroAIDS Tissue Consortium Statistics and Data Coordinating CenterU01MH083545 · NIMH · INDIANA UNIVERSITY INDIANAPOLIS · PI YIANNOUTSOS, CONSTANTIN THEODORE · 2008 to 2012
$3.3M
NCRR NIH HHS P20 RR 15592NIMH NIH HHS U01 MH083545
6 · The paper itself

Abstract

Many human immunodeficiency virus (HIV) proteins including Tat are produced by HIV-infected astrocytes and secreted into the brain resulting in extensive neuronal damage that contributes to the pathogenesis of HIV dementia. The neuroprotective hormone 17beta-estradiol (E2) is known to negatively regulate the HIV transcriptional promoter in human fetal astrocytes (SVGA cell line) in a Tat-dependent manner. In the present study we extended our investigation in HIV-infected SVGA cells and found a reduction in HIV p24 levels following E2 treatment in comparison to control. Although many E2-mediated events occur through estrogen receptor alpha (ERalpha), we found low levels of ERalpha mRNA and failed to detect ERalpha protein in SVGA cells. Paradoxically, when ERalpha was overexpressed the E2-mediated decrease in Tat transactivation of the promotor was prevented. To determine whether ERalpha expression is altered in the human brain following HIV infection, postmortum hippocampal tissue was obtained from cognitively normal HIV- and HIV+ patients, patients diagnosed with either mild cognitive/motor disorder (MCMD) or HIV-associated dementia (HAD). Immunohistochemistry and quantitative real-time PCR (qRT-PCR) for ERalpha and glial fibrillary acidic protein (GFAP) showed that ERalpha mRNA levels were not significantly different between groups, while GFAP increased in the hippocampus in the HIV+ compared to the HIV- group and was decreased in the MCMD and HAD subgroups compared to HIV+ controls. Notably the ratio of ERalpha-positive reactive astrocytes to total reactive astrocytes increased and significantly correlated with the severity of cognitive impairment following HIV infection. The data suggest that E2 would have the most dramatic effect in reducing HIV transcription early in the disease process when the subpopulation of astrocytes expressing ERalpha is low.

Indexed as

AstrocytesNeuroprotective AgentsAIDS Dementia ComplexCell LineEstrogen Receptor alphaEstrogensGene Expression RegulationGlial Fibrillary Acidic ProteinHippocampusHIV-1HumansTranscription, GeneticEstrogen Receptor alphaEstrogensGlial Fibrillary Acidic ProteinNeuroprotective Agents

Identifiers

PMID19886840
PMCPMC2828252
OpenAlexW2031044038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.